Galapagos NV [GLPGA] vs Pharming Group N.V [PHARM] Detailed Stock Comparison

Galapagos NV

EURONEXT
Loading...

Pharming Group N.V.

EURONEXT
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Galapagos NV wins in 13 metrics, Pharming Group N.V. wins in 6 metrics, with 0 ties. Galapagos NV appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Galapagos NV Pharming Group N.V. Better
P/E Ratio (TTM) 5.10 57.15 Galapagos NV
Price-to-Book Ratio 0.50 4.31 Galapagos NV
Debt-to-Equity Ratio 0.21 41.78 Galapagos NV
PEG Ratio -6.32 46.77 Pharming Group N.V.
EV/EBITDA -2.39 23.94 Pharming Group N.V.
Profit Margin (TTM) 28.85% 0.76% Galapagos NV
Operating Margin (TTM) 88.00% 2.84% Galapagos NV
EBITDA Margin (TTM) 88.00% 2.84% Galapagos NV
Return on Equity 10.42% 1.02% Galapagos NV
Return on Assets (TTM) 8.87% 4.55% Galapagos NV
Free Cash Flow (TTM) $-271.32M $53.95M Pharming Group N.V.
1-Year Return -1.66% -21.83% Galapagos NV
Price-to-Sales Ratio (TTM) 1.46 2.71 Galapagos NV
Enterprise Value $-1.36B $810.05M Pharming Group N.V.
EV/Revenue Ratio -1.22 2.52 Pharming Group N.V.
Gross Profit Margin (TTM) 99.95% 80.19% Galapagos NV
Revenue per Share (TTM) $17 $1 Galapagos NV
Earnings per Share (Diluted) $4.85 $0.00 Galapagos NV
Beta (Stock Volatility) 0.15 0.12 Pharming Group N.V.

Galapagos NV vs Pharming Group N.V. Stock Performance Analysis

Loading Price Chart...

GLPGA
PHARM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Galapagos NV0.00%1.96%6.58%-12.43%-6.24%-11.43%
Pharming Group N.V.-0.40%0.00%0.00%-21.28%-21.28%-21.28%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Galapagos NV-1.66%-35.89%-60.48%-44.69%414.23%177.11%
Pharming Group N.V.-21.83%-21.83%-21.83%-21.83%-21.83%-21.83%

Performance & Financial Health Analysis: Galapagos NV vs Pharming Group N.V.

MetricGLPGAPHARM
Market Information
Market Cap i€1.63B€1.02B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i57,55311,520,576
90 Day Avg. Volume i88,73412,234,806
Last Close€24.94€1.11
52 Week Range€22.62 - €32.74€0.84 - €1.82
% from 52W High-23.82%-38.94%
All-Time High€252.90 (Feb 17, 2020)€459.55 (Jul 10, 2000)
% from All-Time High-90.14%-99.76%
Growth Metrics
Quarterly Revenue Growth10.93%0.15%
Quarterly Earnings Growth29.91%0.86%
Financial Health
Profit Margin (TTM) i0.29%0.01%
Operating Margin (TTM) i0.88%0.03%
Return on Equity (TTM) i0.10%0.01%
Debt to Equity (MRQ) i0.2141.78
Cash & Liquidity
Book Value per Share (MRQ)€49.11€0.33
Cash per Share (MRQ)€45.50€0.26
Operating Cash Flow (TTM) i€-257,456,000€46.72M
Levered Free Cash Flow (TTM) i€344.64M€58.63M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Galapagos NV vs Pharming Group N.V.

MetricGLPGA (Apr 24, 2026)PHARM (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i5.1057.15
Forward P/E i-6.3246.77
PEG Ratio i-6.3246.77
Price to Sales (TTM) i1.462.71
Price to Book (MRQ) i0.504.31
Market Capitalization
Market Capitalization i€1.63B€1.02B
Enterprise Value i€-1,355,567,744€810.05M
Enterprise Value Metrics
Enterprise to Revenue i-1.222.52
Enterprise to EBITDA i-2.3923.94
Risk & Other Metrics
Beta i0.150.12
Book Value per Share (MRQ) i€49.11€0.33

Financial Statements Comparison: Galapagos NV vs Pharming Group N.V.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricGLPGA (2025)PHARM (2025)
Revenue/Sales i1.11B376.13M
Cost of Goods Sold i29.74M45.50M
COGS % of Revenue i2.7%12.1%
Gross Profit i1.08B330.63M
Gross Margin i97.3%87.9%
Research & Development i459.42M100.37M
Operating Income (EBIT) i501.39M20.88M
Operating Margin i45.1%5.6%
EBITDA i604.67M36.28M
EBITDA Margin i54.4%9.6%
Pre-Tax Income i300.87M12.85M
Pre-Tax Income % of Revenue i27.1%3.4%
Income Tax i-18.62M10.31M
Income Tax % of Revenue i-1.7%2.7%
Net Income (Profit) i320.88M2.54M
Profit Margin i28.9%0.7%

Balance Sheet & Liquidity Metrics

MetricGLPGA (2025)PHARM (2025)
Cash & Equivalents i87.87M145.31M
Total Current Assets i3.08B299.47M
Total Current Assets % of Revenue i276.9%79.6%
Total Current Liabilities i152.86M115.79M
Total Current Liabilities % of Revenue i13.7%30.8%
Long-Term Debt i5.19M107.07M
Long-Term Debt % of Revenue i0.5%28.5%
Total Shareholders Equity i3.24B277.10M
Retained Earnings i210.58M-272.98M
Retained Earnings % of Revenue i18.9%-72.6%
Property, Plant & Equipment i3.18M6.12M

Cash Flow Statement Comparison

MetricGLPGA (2025)PHARM (2025)
Operating Cash Flow i-594.79M47.47M
Operating Cash Flow % of Revenue i-53.5%12.6%
Capital Expenditures i-13.24MN/A
Free Cash Flow i-271.32M53.95M
FCF Margin i-24.4%14.3%
Debt Repayment i-3.27M-4.25M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricGLPGAPHARM
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i65.90M701.68M
Float Shares i44.54M690.78M
% Held by Insiders i25.36%1.89%
% Held by Institutions i32.49%20.99%
% Held by Public i42.15%77.12%

Dividend Analysis & Yield Comparison: Galapagos NV vs Pharming Group N.V.

MetricGLPGAPHARM
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A